Live Q&A: Castration-Sensitive Prostate Cancer: Navigating the Current Diagnostic and Treatment Landscape

CMEO Webcast

Premiere Date: Thursday, November 18, 2021

This activity offers CE credit for:

  1. ABIM (MOC)
  2. Medicine (accme)
  3. Nursing (ANCC)
  4. Pharmacy (acpe)
  5. PA (aapa)
  6. Other


All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Friday, November 18, 2022

Begin Activity

Faculty


Cora N. Sternberg, MD, FACP
Cora N. Sternberg, MD, FACP (Moderator)
Clinical Director, Englander Institute for Precision Medicine
Professor of Medicine
Sandra and Edward Meyer Cancer Center
Weill Cornell Medicine
New York, NY

Neal D. Shore, MD, FACS
Neal D. Shore, MD, FACS 
Director, CPI, Carolina Urologic Research Center
Chief Surgical Officer, Genesis Care, US
Atlantic Urology Clinics
Myrtle Beach, SC

Statement of Need

Prostate cancer is the most common cancer in men and the fourth leading cause of cancer death in men. In order to apply current treatment guidelines, it is critical that prostate cancer be accurately staged. Updates to the Gleason scoring system and the introduction of grade groups have improved prognostication and risk stratification. Clinicians need to be able to interpret and act upon pathology reports.

This live Q&A is a follow-up to the first episode of the CME Outfitters podcast series on castration-sensitive prostate cancer (CSPC), which outlined the current state of staging in CSPC and clarified the findings of reports detailing the pathology of prostate cancer specimens.
Click here to view the full activity ahead of this live Q&A.

Learning Objectives

At the end of this CME/CE activity, participants should be able to:

  • Outline the current state of staging in CSPC.
  • Interpret the findings of reports detailing the pathology of prostate cancer specimens.

Financial Support

Supported by an educational grant from Astellas and Pfizer, Inc.

Target Audience

Urologists, medical oncologists, PAs, nurse practitioners, nurses, and pharmacists

Credit Information

Jointly Accredited Provider
JA

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



Physicians (ACCME):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC):
This activity is designated for .5 contact hours.

Note to Nurse Practitioners:
Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)™ from Jointly Accredited Organizations. Nurse practitioners can also apply for credit through their state boards.

Pharmacists (ACPE):
This knowledge-based activity is approved for .5 contact hours (0.05 CEUs) of continuing pharmacy credit (JA0007185-0000-21-049-L01-P).

PAs (AAPA):
AAPA CME Outfitters has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .5 AAPA Category 1 CME credits. Approval is valid until expiration date. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Sternberg reports that she is a consultant for Astellas Pharma US, Inc.; AstraZeneca; Bristol-Myers Squibb Company; Foundation Medicine, Inc.; Immunomedics, Inc./Gilead Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Merck Sharp & Dohme Corp.; National Cancer Institute; Pfizer Inc.; Genentech, Inc./Roche; Sanofi Genzyme; and UroToday.

Dr. Shore reports that he is on the speakers bureau for AstraZeneca; Astellas Pharma US, Inc.; Bayer; Clovis Oncology; Foundation Medicine, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; and Pfizer Inc. He reports that he is a consultant for AbbVie Inc.; Amgen Inc.; Astellas Pharma US, Inc.; AstraZeneca; Bayer; Boston Scientific Corporation; Bristol-Myers Squibb Company; Clovis Oncology; Cold Genesys; Dendreon Pharmaceutical LLC; Exact Imaging; Exact Sciences Corporation; FerGene Inc.; Foundation Medicine, Inc.; GenesisCare; Invitae Corporation; Janssen Pharmaceuticals, Inc.; MDxHealth; Merck & Co., Inc.; Myovant Sciences; Myriad Genetics, Inc.; Nymox Pharmaceuticals Corporation; Pacific Edge; Pfizer Inc.; Phosphorous; PreVie; Propella Therapeutics, Inc.; Sanofi Genzyme; Sesen Bio; Speciality Networks, LLC; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.

David Modrak, PhD (planning committee) has no disclosures to report.

Evan Luberger (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

CME Outfitters, LLC and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


This document was last modified on:

PDQ-065-111821-42